Page last updated: 2024-10-31

neostigmine and Respiratory Distress Syndrome, Newborn

neostigmine has been researched along with Respiratory Distress Syndrome, Newborn in 1 studies

Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.

Respiratory Distress Syndrome, Newborn: A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
McLean, WT1
McKone, RC1

Other Studies

1 other study available for neostigmine and Respiratory Distress Syndrome, Newborn

ArticleYear
Congenital myasthenia gravis in twins. Identical twins with crises in the newborn period.
    Archives of neurology, 1973, Volume: 29, Issue:4

    Topics: Diseases in Twins; Female; Genes, Recessive; Humans; Infant, Newborn; Infant, Newborn, Diseases; Mal

1973